USA flag logo/image

An Official Website of the United States Government

Sustained Regeneration of Soft Tissue Defects

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43GM099325
Solicitation Year:
2012
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA11-096
Small Business Information
Spectrasilk, Inc.
PO Box 53059 Medford, MA 02153
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Sustained Regeneration of Soft Tissue Defects
Agency: HHS
Contract: 1R43GM099325-01A1
Award Amount: $150,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Summary There is no clinical option to restore large soft tissue defects to normal tissue structure and function. Lipoaspriates and fat transfers offer some benefits, but retention of volume and avoidance of recurring repeats of the surgeries is a major problem for large defects, such as those from surgery and trauma. Thus, sustained (retention of volume during remodeling in vivo to normal restored tissue states) soft tissue reconstruction is a major unmet clinical need,with origins in disease, surgeries and trauma. All current clinical approaches, including surgical flaps, artificial fillers, and free fat transplant ll present significant limitations. In particular, these options fail to restore native tissue size, sapeand function over extended time frames; losing volume within three months of surgery. Therefore there is a critical need for new options in the field that would restore large soft tissu defects in terms of retention of volume for at least one year duringtissue integration and regeneration in vivo. To address this need, we propose to implement a 3D porous silk-based protein biomaterial scaffold system in combination with lipoaspirate. The unique features of the system include the ability to stabilize the silk protein matrix used in vivo for more than a year yt achieve full native tissue regeneration over time, the ability to support cells and promote adipogenesis and vasculogenesis, the mechanical robustness of the scaffold system to support tissue structure and volume over time, and the use of a biocompatible, FDA approved, biomaterial (silk) in the process. The hypothesis is that a biomaterial system can be designed for soft tissue reconstruction needs where size and shape at the implant site can be retained for at least one year during vascularized adipose formation, and allow full integration with native tissue with complete remodeling over time. Our comprehensive preliminary data support the feasibility of the plan and the aim is designed to demonstratethe best path forward in a three month in vivo mouse study. We will assess variables of cell adhesion sites (RGD), and the role of lipoaspirate in the process. Unseeded control scaffolds will also be studied. Outcomes will include assessments against othercommonly considered biodegradable polymeric materials (collagen, PLGA, PCL): (a) retention of size and shape for 3 months in vivo, and (b) vascularized adipose tissue distribution in the scaffold, and (c) integration with surrounding tissue. At the end ofthe study we anticipate being in a position to pursue long term large animal studies and then human clinical trials. PUBLIC HEALTH RELEVANCE: The need for stable soft tissue reconstruction is large and growing due to severe trauma, diseases suchas cancer and surgery. However, current clinical options are limited. The proposed program will address this need and fill the current gap in available clinical options in terms of retention of volume and shape of the defect site during tissue regeneration.

Principal Investigator:

Jonathan Kluge
617-627-2580
jonathan.kluge@tufts.edu

Business Contact:

Keleigh A. Sanford
339-221-3038
spectrasilk@gmail.com
Small Business Information at Submission:

SPECTRASILK, INC.
PO Box 53059 Medford, MA 02153

EIN/Tax ID: 126210299
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No